Dissemination (Meeting Coverage)

Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that adavosertib, a Wee1 inhibitor, was effective in patients with PARP inhibitor-resistant ovarian cancer when given alone and in...

TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...

Earlier detection of primary ovarian tumor could extend survival in some patients When complete debulking is feasible, primary debulking surgery (PDS) may be superior to neoadjuvant chemotherapy (NACT) in women with high-grade...

Good anti-tumor activity and manageable safety profile seen When added to concurrent chemoradiation therapy (cCRT), pembrolizumab—a highly selective humanized monoclonal anti-PD-1 antibody—showed promising antitumor activity in...

Confirmed response seen in patients who relapse after osimertinib Patients with non-small cell lung cancer (NSCLC) who had relapsed after an initial response to osimertinib therapy may benefit from treatment with the combination...

Objective response observed at 1.4 months Targeted therapies have greatly improved outcomes in non-small cell lung cancer (NSCLC), but for patients who progress on those therapies, the prognosis is poor, which explains the...

Survival benefit seen in early-stage HER-2 negative breast cancer with BRCA1/2 mutations Adding 12 months of treatment with the PARP inhibitor olaparib following completion of standard therapies significantly increased invasive...

Significant improvements in mortality among non-small cell lung cancer (NSCLC) cancer patients have been reported over the past 2 decades, according to Surveillance, Epidemiology, and End Results Program (SEER) data. The timing...

Liquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence in patients with early-stage non-small cell lung cancer (NSCLC). Due to low ctDNA levels in...

Herpes zoster (HZ) is prevalent in patients with Chronic Lymphocytic Leukemia (CLL) and affects younger patients who require chemotherapy. The risk of developing HZ increases in recipients of first and second line chemotherapy....

Survival is significantly improved by calendar period among patients diagnosed after 2004 and treated in the era of advanced therapies. Females and younger patients had a higher probability of long term survival. The survival of...

A 24-month phone and app/web-based diet and physical activity intervention that was successful for weight loss in the general population did not result in greater weight loss or improvement in cardiovascular (CV) risk factors...

This study demonstrated for the first time that human peripheral blood mononuclear cells (PBMCs) from chronic lymphocytic leukemia (CLL) patients can be converted into NK cells, CD8+ T cells, NKT cells, and TCRγδ T cells...

Palliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial.   Integrated palliative and oncology care (IPC) as part of...

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with...

Evidence indicates that balancing treatment efficacy with complication risk is critically important for older adults with non-Hodgkin’s lymphoma (NHL); however, the survival outcomes, rates of toxicities, and healthcare...

Although previous studies suggest positive outcomes with novel salvage therapies for patients with relapsed/refractory classic Hodgkin’s lymphoma who are eligible for autologous stem cell transplant, the efficacies and outcomes...

Prior research indicates that survivors of non-Hodgkin’s lymphoma are at increased risk of secondary malignancies. However, data are lacking on long-term risk and whether such risk differs by treatment modality. Investigators...

To determine whether a correlation exists between baseline tumor burden and early tumor progression based on imaging in patients with diffuse large B-cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL), researchers analyzed...